Pentanoic acid, 4-methyl, 1-methylethyl ester | 25415-69-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Pentanoic acid, 4-methyl, 1-methylethyl ester
• 英文别名: propan-2-yl 4-methylpentanoate
• CAS: 25415-69-4
• 化学式: C₉H₁₈O₂
• mdl: MFCD21101270
• 分子量: 158.24
• InChiKey: SVIJAVIDKRORLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US20160009637A1

  公开（公告）日：2016-01-14

  The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

  本发明涉及一种阳离子脂质，其具有位于脂质基团（例如，疏水链）的中部或远端部位的一个或多个可生物降解的基团。这些阳离子脂质可以被纳入脂质颗粒中，用于传递活性剂，例如核酸。该发明还涉及包括中性脂质、能够减少聚集的脂质、本发明的阳离子脂质以及可选地固醇的脂质颗粒。脂质颗粒还可以进一步包含治疗剂，如核酸。
• AMINOTHIAZOLE DERIVATIVE
  申请人：Yabuuchi Tetsuya

  公开号：US20120220767A1

  公开（公告）日：2012-08-30

  A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which has a PI3 kinase γ inhibitory effect and is useful as a prophylactic or therapeutic agent for articular rheumatism, Crohn's disease, irritable colitis, Sjoegren's syndrome, multiple sclerosis, systemic lupus erythematosus, asthma, atopic dermatitis, arteriosclerosis, organ transplant rejection, cancer, retinopathy, psoriasis, arthrosis deformans, age-related macular degeneration, type II diabetes, insulin resistance, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipemia, etc.

  由式（1）表示的化合物或其药学上可接受的盐，具有PI3激酶γ抑制作用，可用作关节风湿、克罗恩病、肠易激综合征、干燥综合征、多发性硬化、系统性红斑狼疮、哮喘、特应性皮炎、动脉硬化、器官移植排斥、癌症、视网膜病变、牛皮癣、关节病变、年龄相关性黄斑变性、2型糖尿病、胰岛素抵抗、肥胖、非酒精性脂肪肝病（NAFLD）、非酒精性脂肪性肝炎（NASH）、高脂血症等疾病的预防或治疗剂。
• INFRARED SENSOR, NEAR-INFRARED ABSORBING COMPOSITION, CURED FILM, NEAR-INFRARED ABSORBING FILTER, IMAGE SENSOR, CAMERA MODULE, AND COMPOUND
  申请人：FUJIFILM Corporation

  公开号：US20170012072A1

  公开（公告）日：2017-01-12

  Provided are an infrared sensor, a near-infrared absorbing composition, a cured film, a near-infrared absorbing filter, an image sensor, a camera module, and a compound. An infrared sensor 100 which has an infrared transmitting filter 113 and a near-infrared absorbing filter 111 and detects objects by detecting light having wavelengths of 700 nm or longer and shorter than 900 nm, in which the near-infrared absorbing filter 111 includes a near-infrared absorbing substance having a maximum absorption wavelength at a wavelength of 700 nm or longer and shorter than 900 nm.

  提供了一个红外传感器、一个近红外吸收组合物、一个固化膜、一个近红外吸收滤光片、一个图像传感器、一个摄像头模块和一个化合物。具有红外透射滤光片113和近红外吸收滤光片111的红外传感器100，通过检测波长为700纳米或更长且小于900纳米的光来检测物体，其中近红外吸收滤光片111包括具有在700纳米或更长且小于900纳米波长处的最大吸收波长的近红外吸收物质。
• Pyrrolopyridazinone Compound
  申请人：Hagihara Masahiko

  公开号：US20090036453A1

  公开（公告）日：2009-02-05

  The present invention discloses a pyrrolopyridazinone compound represented by the formula (1): wherein R 1 represents C 1 -C 2 alkyl group or halogeno C 1 -C 2 alkyl group, R 2 repersents C 3 -C 5 cycloalkyl group, (C 3 -C 5 cycloalkyl)C 1 -C 2 alkyl group or C 1 -C 3 alkyl group, R 3 represents hydrogen atom, or methylene group or cis-vinylene group for forming substituted oxygen-containing hetero ring in combination with group —O—R 2 , R 4 represents hydrogen atom, halogen atom, C 1 -C 8 alkyl group, C 2 -C 6 alkenyl group, C 2 -C 6 alkynyl group, hydroxy C 3 -C 6 alkenyl group, hydroxy C 3 -C 6 alkynyl group, C 1 -C 6 alkyl group substituted by substituent(s) selected from Substituent group (a), C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), “C 1 -C 3 alkyl group which is substituted by C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), and which may be substituted by a hydroxy group”, an aromatic ring group or heteroaromatic ring group each of which may be substituted by a substituent(s) selected from Substituent group (c) or “C 1 -C 2 alkyl group which is substituted by aromatic ring group or heteroaromatic ring group each of which may be substituted by group(s) selected from Substituent group (c), and which may be substituted by a hydroxy group”, Substituent group (a) represents a halogen atom, hydroxy group, cyano group, carboxy group, C 1 -C 5 alkoxy group, halogeno C 1 -C 4 alkoxy group, C 3 -C 6 cycloalkoxy group, (C 3 -C 6 cycloalkyl)C 1 -C 2 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyl group, C 2 -C 4 alkanoyloxy group or C 1 -C 4 alkyl-substituted amino group, Substituent group (b) represents a hydroxy group or a halogen atom, Substituent group (c) represents a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, C 1 -C 5 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyloxy group, C 1 -C 4 alkyl-substituted amino group or a C 1 -C 4 alkyl group which may be substituted by a substituent(s) selected from the group consisting of (a halogen atom, a hydroxy group and a carboxy group), or a pharmaceutically acceptable salt thereof.

  本发明公开了一种由式（1）表示的吡咯吡啶二酮化合物：其中，R1代表C1-C2烷基或卤代C1-C2烷基，R2代表C3-C5环烷基、（C3-C5环烷基）C1-C2烷基或C1-C3烷基，R3代表氢原子，或与基团-O-R2结合形成取代含氧杂环的亚甲基或顺式乙烯基，R4代表氢原子、卤素原子、C1-C8烷基、C2-C6烯基、C2-C6炔基、羟基C3-C6烯基、羟基C3-C6炔基、由从取代基团（a）中选择的取代基团取代的C1-C6烷基，可由从取代基团（b）中选择的取代基团取代的C3-C6环烷基，可由从取代基团（b）中选择的取代基团取代的C1-C3烷基，且可由羟基取代，芳香环基或杂芳香环基，每个都可由从取代基团（c）中选择的取代基团取代或由取代基团（c）选择的基团取代的C1-C2烷基，且可由羟基取代，取代基团（a）表示卤素原子、羟基、氰基、羧基、C1-C5烷氧基、卤代C1-C4烷氧基、C3-C6环烷氧基、（C3-C6环烷基）C1-C2烷氧基、C1-C4烷氧羰基、C2-C4酰基、C2-C4酰氧基或C1-C4烷基取代的氨基基团，取代基团（b）表示羟基或卤素原子，取代基团（c）表示卤素原子、羟基、氰基、硝基、羧基、C1-C5烷氧基、C1-C4烷氧羰基、C2-C4酰氧基、C1-C4烷基取代的氨基基团或可由从由卤素原子、羟基和羧基组成的基团中选择的取代基团取代的C1-C4烷基，或其药学上可接受的盐。
• METHOD FOR PRODUCING STEROID COMPOUND
  申请人：Takehara Jun

  公开号：US20100063272A1

  公开（公告）日：2010-03-11

  It is an object of the present invention to provide a novel method for producing a steroid compound. The present invention provides a method for producing 5β-3,7-dioxocholanic acid or an ester derivative thereof, using, as a raw material, a sterol having double bonds at position 5 and at position 24, such as cholesta-5,7,24-trien-3β-ol, ergosta-5,7,24(28)-trien-3β-ol, desmosterol, fucosterol, or ergosta-5,24(28)-dien-3β-ol, via the following 4 steps: (I) a step involving oxidation of a hydroxyl group at position 3 and isomerization of a double bond at position 5 to position 4; (II) a step involving the oxidative cleavage of a side chain to convert position 24 to a carboxyl group or an ester derivative thereof; (III) a step of introducing an oxygen functional group into position 7; and (IV) a step of constructing a 5β configuration by reductive saturation of a double bond at position 4.

  本发明的目的是提供一种新型类固醇化合物的制备方法。本发明提供了一种以具有5号和24号位置双键的类固醇（如胆甾-5,7,24-三烯-3β-醇、麦角甾-5,7,24(28)-三烯-3β-醇、脱甾醇、褐藻甾醇或麦角甾-5,24(28)-二烯-3β-醇）为原料，通过以下4个步骤制备5β-3,7-二氧代胆甾酸或其酯衍生物：(I) 氧化3号羟基并异构化5号双键至4号的步骤；(II) 氧化断裂侧链以将24号位置转化为羧基或其酯衍生物的步骤；(III) 在7号位置引入氧功能团的步骤；和(IV) 通过还原饱和4号位置的双键构建5β构型的步骤。

表征谱图